Home » Newsletters » BioWorld

BioWorld

May 13, 2008

View Archived Issues

Despite Tough Market, Aldagen's IPO Seeks $81M for Cell Therapy

With its lead cell therapy program in a pivotal study, Aldagen Inc. has decided to brave the public markets. (BioWorld Today) Read More

Cell Genesys Snagging $30M to Push Late-Stage GVAX

Long-Term UK Bio Investor Prelude Trust Calling it Quits

Novelos Antitumor Drug Hits Efficacy Mark Early in Trial

Other News To Note

Earnings Roundup

U.S. Patent Disclosures

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 12, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...